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Methods: We investigated the ability of FDX to prevent I/R injury in vivo, in a 
model of transient coronary ligation, and ex vivo in a model of crystalloid-perfused 
isolated-heart. In the in vivo model, 40-min of myocardial ischemia was followed 
by 120-min of reperfusion. FDX (10mg/kg) was injected intraperitoneally 10-min 
before reperfusion. In the isolated-heart model, FDX (0.1mg/ mL) was administrated 
in the recirculating buffer. In both models, infarct size was assessed after 120-min 
of reperfusion. Myocardial tissues were collected at 15 – and 30-min reperfusion for 
western-blots analysis.
Results: In vivo, FDX decreased infarct size by 29% (44,28% vs 61,98% in 
FDX-treated rats and controls respectively, p<0.05). FDX induced a signifi cant 
phosphorylation of STAT-3 and GSK3β as compared with controls. Addition of 
AG490, an inhibitor of JAK/STAT pathway before I/R prevented the phosphorylation 
of STAT-3 and GSK3β and abolished the FDX-induced cardioprotection. On the 
contrary, FDX had no effect on infarct size and hemodynamic parameters in the 
isolated-heart model.
Conclusion: FDX decreased I/R injury in vivo but not in a crystalloid-perfused 
isolated-heart. The protective effect was mediated through the phosphorylation of 
STAT-3. In our experimental conditions, FDX needed whole blood to be protective 
but its benefi cial effect was not directly related to anticoagulant effect but to the 
activation of the SAFE pathway.
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Background: Vascular endothelial growth factor (VEGF) activates endothelial 
cells. Coronary endothelial dysfunction is believed to be involved in cardiac ischemia-
reperfusion (IR) injury. We examined whether VEGF infl uences IR outcome in mice 
through the involvement of VEGFR2 receptors. We also investigated the role of 
mitochondrial function, a determinant of apoptosis, by assessing permeability transition 
pore (mPTP) opening and mitochondrial respiratory function.
Methods: In protocol 1, mice underwent 30 min of ischemia followed by 180 
min of reperfusion. Area at risk (AR) and myocardial infarct size (IS) were assessed 
by planimetry and IS/AR ratios (%) were calculated. Mice received either saline or 
VEGF (30 μg/kg) as an IV bolus, 5 min before reperfusion. Two groups were pretreated 
with the VEGFR2 antagonist SU1498 (50 mg/kg, ip), 15 min before ischemia, alone or 
before VEGF treatment. In protocol 2, mice underwent either no intervention (sham) 
or 30 min of ischemia followed by 15 min of reperfusion. Mice received either saline 
or VEGF (30 μg/kg) 5 min before reperfusion. Cardiac mitochondria were isolated to 
assess either calcium retention capacity (CRC) by spectrofl uorimetry or mitochondrial 
oxygen consumption by oxygraphy.
Results: In IR, VEGF reduced IS/AR by 57% (p<0.01 vs saline). Pretreatment 
with SU1498 abolished the benefi cial effect of VEGF (p<0.05). IR induced mPTP 
opening (decrease in CRC by 35%, p<0.01 vs sham) and impaired mitochondrial 
respiratory function (decrease in state 3 and state 4 respiration by 51% and 43%, 
p<0.01 vs sham). VEGF increased CRC by 37% compared to saline (p<0.05), and 
improved mitochondrial respiratory function by 71% for state 3 and 51% for state 
4 (p<0.01).
Conclusion: These data show that single IV administration of VEGF has strong 
cardioprotective effect in IR through VEGFR2 activation. They suggest that the IS 
reducing effect of VEGF is mediated, at least in part, by improvement of IR-induced 
mitochondrial dysfunction.
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Endoplasmic reticulum stress contributes to heart protection induced by 
cyclophilin D inhibition
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Inhibition of Cyclophilin D (CypD) translocation is effi cient to limit lethal 
reperfusion injury through inhibition of mitochondrial permeability transition (MPT). 
Recently, in our lab, we showed that CypD defi ciency or inhibition induced an 
endoplasmic reticulum (ER) stress can have both benefi cial or deleterious effects in 
cell survival. Therefore, we purposed that ER stress could play an essential role in 
cardioprotection induced by CypD defi ciency or inhibition. 
CypD-KO and NIM-811 (a CypD inhibitor) -treated mice were subjected to an 
ischemia-reperfusion (I/R). Infarct size was evaluated along with ER stress makers. 
CypD absence induced a decrease in infarct size (8±1 vs 20±4% of left ventricular 
(LV); p<0.01) that was abolished by an ER stress inhibitor TUDCA (21±4% of LV, 
p<0.01), whereas TUDCA alone was cardioprotective. Moreover, CypD-defi cient mice 
displayed an increase in ER stress proteins such as eukaryotic Initiation factor 2α or 
Glucose-Regulated protein 78, and in mRNA content for X-box Binding Protein 1 
splicing. Same results were obtained with NIM-811 treated-mice.
To conclude, in addition to MPT, ER stress is an essential factor in protecting 
the heart against I/R, by CypD inhibition.
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Background: Acute myocardial infarction is a leading cause of death worldwide. 
Although highly benefi cial, reperfusion of myocardium is associated with reperfusion 
injury. Pharmacologic inhibition of factor Xa has been shown to attenuate ischemia-
reperfusion (I/R) injury but the cellular mechanism is poorly understood. 
Objectives: To determine the role of blood in fondaparinux (FDX) -induced 
cardioprotection and the involvement of RISK and SAFE pathways, two major 
survival signalling cascades commonly associated with protection against I/R injury.
Archives of Cardiovascular Diseases Supplements (2013), 5, 18-19 19
© Elsevier Masson SAS. All rights reserved.
104
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Remote ischemic preconditioning (RIPC) has emerged as an attractive strategy in 
clinical settings. Despite convincing evidence of the critical role played by circulating 
humoral mediators, their actual identities remain unknown. In this study, we aimed to 
identify RIPC-induced humoral mediators using a proteomic approach.
Methods and results: Rats were exposed to 10-min limb ischemia followed 
by 5- (RIPC 5’) or 10-min (RIPC 10’) reperfusion prior to blood sampling. The 
control group only underwent blood sampling. Plasma samples were analyzed using 
surface-enhanced laser desorption and ionization – time of fl ight – mass spectrometry 
(SELDI-TOF-MS). Three protein peaks were selected for their signifi cant increase 
in RIPC 10’. They were identifi ed and confi rmed as apolipoprotein A-I (ApoA-I). 
Additional rats were exposed to myocardial ischemia-reperfusion (I/R) and assigned 
to one of the following groups: RIPC + myocardial infarction (MI) (10-min limb 
ischemia followed by 10-min reperfusion initiated 20 minutes prior to myocardial 
I/R), ApoA-I + MI (10mg/kg ApoA-I injection 10 minutes before myocardial I/R), 
and MI (no further intervention). In comparison with untreated MI rats, RIPC reduced 
infarct size (52.2±3.7% in RIPC + MI vs 64.9±2.6% in MI; p<0.05). Similarly, ApoA-I 
injection decreased infarct size (50.9±3.8%; p<0.05 vs MI).
Conclusion: RIPC was associated with a plasmatic increase in ApoA-I. 
Furthermore, ApoA-I injection before myocardial I/R recapitulated the cardioprotection 
offered by RIPC in rats. This data suggests that ApoA-I may be a protective blood-borne 
factor involved in the RIPC mechanism.
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Myocardial ischemia and reperfusion lead to cardiomyocyte apoptosis. Caspases, 
a conserved family of proteases, are mainly involved in this cell death program. Indeed, 
after reperfusion, there is a peak of TNF-α leading to caspase-8 activation responsible 
of reperfusion injury. Caspase-2, an initiator caspase, is the most conserved caspase 
among species and other caspases. However, its role in cardiac reperfusion injury is 
unknown. The goal of this study was to determine the role and the activation mode 
of caspase-2 in a rat model of ischemia-reperfusion. To this aim, rats were subjected 
to 30 min ischemia followed by 1h, 6h or 24h of reperfusion. Western blot analyses 
revealed that caspase-2 is expressed in left ventricular. Caspase-2 activity increases 
during the fi rst hour after reperfusion (<6h) and precedes that of caspase-8 (6h) and 
caspase-9 and -3 (24h). In addition, the cleavage of the pro-apoptotic protein BID 
(tBID) and cytochrome c release occur at 24h of reperfusion. An intraperitoneal 
injection of TRP601 (caspase-2/-7 inhibitor), 15 min prior the reperfusion, prevents BID 
cleavage, cytochrome c release, caspase-3 cleavage and reperfusion injury. In parallel, 
an application of TNF-α on adult ventricular cardiomyocytes activates caspase-2 and 
caspase-8. Pharmacological inhibition of caspase-2 by TRP601 prevents caspase-8 
activity whereas caspase-8 inhibition by QVDOPH does not affect caspase-2 activity. 
All together, these results indicate that caspase-2 activation is an early event in the 
execution of TNF-α-induced intrinsic apoptotic pathway. Therefore, pharmacological 
inhibition of caspase-2 represents a potential therapeutic strategy to prevent reperfusion 
injuries.
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Administration of a single dose of adenosine downstream the occlusion to 
reduce reperfused infarct size
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Although reperfusion is the best way to reduce damage induced by ischemic 
period, phenomena present during the reperfusion period, called reperfusion injury, 
contribute to attenuate its benefi cial effect. To attenuate reperfusion injury, different 
drugs have been successfully used such as adenosine (ADO). However, we have 
hypothesized that an unique dose of ADO, administered downstream the occlusion 
site, could be benefi cial to reduce infarct size. The present project proposes to test 
the ability of different doses of ADO to attenuate infarct size.
Male pigs (35-40 kg) underwent myocardial infarction by the occlusion of the left 
anterior descending artery just distal to the second diagonal branch by infl ated balloon 
catheter for 50 minutes followed by a period of reperfusion. Myocardial infarct size (I) 
expressed as percent of area at risk (AR) was estimated after 3h of reperfusion. Three 
different doses of ADO were tested (2mg, 4mg or 8mg/2 mL of saline; A2; A4; A8) 
and two ways of administration were performed: intra and extracoronary. Two minutes 
before the beginning of the reperfusion, ADO was administered for more than two 
minutes by intracoronary way via the balloon catheter downstream of the occlusion. 
In another group, ADO (8mg/2 mL) was administered by extracoronary way, upstream 
of the occlusion A 8 (P). Placebo group (P) received equivalent volume of 0.9% NaCl 
(2 mL) by intracoronary way via the balloon catheter (fi gure).
We observed a signifi cant reduction of infarct size in the group A4 and A8, but 
not in the group A2 and A 8 (P) compared to P group (see fi gure). 
These results show that a single high-dose of ADO reduces infarct size. However, 
this benefi cial effect was lost with lower dose or by the administration of ADO 
upstream of the occlusion, indicating the importance of the site of injection to obtain 
a benefi cial effect. 
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